Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.36 |
| ▸ | KDR | P35968 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124123 | 0.94 | MEN1 (0.46) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2127136 | 0.85 | FGFR1 (0.37) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2125333 | 0.85 | FGFR1 (0.37) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2693461 | 0.85 | TSHR (0.41) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL4070185 | 0.84 | ALDH1A1 (0.38) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2693716 | 0.82 | KMT2A (0.39) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2129624 | 0.80 | CXCR4 (0.42) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2695192 | 0.80 | MEN1 (0.38) | MEN1KMT2AFGFR1FGFR2FGFR4 | |
| SCHEMBL2123473 | 0.79 | KMT2A (0.58) | MEN1KMT2AALDH1A1CYP11B1CXCR4 | |
| SCHEMBL2123754 | 0.78 | FGFR1 (0.35) | KMT2AFGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101280-A1 | COMPOUND HAVING SPIRO-BONDED CYCLIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2444402-A1 | COMPOUND HAVING SPIRO-BONDED CYCLIC GROUP AND USE THEREOF | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101280-A1 | COMPOUND HAVING SPIRO-BONDED CYCLIC GROUP AND USE THEREOF | CXCR4, CXCL12, CCR5 | MEN1 2741/4885KMT2A 4122/4885FGFR1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.